TS
HARP

Thomas Steyer’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Thomas Steyer’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,000
Closed -$5.23M – 332
2021
Q1 		$5.23M Buy
+25,000
New +$5.01M 0.03% 182

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Thomas Steyer's HARP Position: Q2 2021 in Review

Thomas Steyer sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2021, closing a stake of 25,000 shares — an estimated $5.23M sold.

Thomas Steyer first reported a position in HARP in Q1 2021 and held it in 1 quarter. The position peaked at $5.23M in Q1 2021. 85 funds tracked by Wall St. Rank hold HARP as of Q2 2021.

  • Thomas Steyer reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Thomas Steyer sold 25,000 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $5.23M.
  • Thomas Steyer first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Thomas Steyer's Harpoon Therapeutics, Inc. Common Stock position peaked at $5.23M in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.